Every 10-Q that Anika Therapeutics Inc (ANIK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ANIK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANIK filings page.
Anika Therapeutics reported Q2 2026 revenue of $32.6 million, up 16% year over year, and net income from continuing operations of $3.3 million versus a loss a year ago. Gross margin rose to 65% from the low‑50% range, helped by higher OEM sales and better manufacturing utilization.
For the first half of 2026, revenue was $62.2 million and the net loss narrowed to $1.7 million. Cash and cash equivalents were $38.4 million with working capital of $77.0 million, and a new $50.0 million revolving credit facility, expandable to $100.0 million, remained undrawn. Customer concentration is high, with J&J MedTech contributing about half of revenue. The company continued FDA interactions on Cingal’s planned NDA and Hyalofast’s PMA review, while executing cost reductions and share repurchases totaling $30.0 million for 2.14 million shares since program inception.
Anika Therapeutics grew its business but remained unprofitable this quarter. Revenue for the three months ended March 31, 2026 rose to $29.6 million, up 13% year over year, driven by stronger OEM sales, especially to J&J MedTech, and higher international OA pain and regenerative product revenue.
Gross margin improved to 64% from 56% as higher volume and lower inventory charges boosted profitability, yet the company posted a net loss of $5.1 million, or $0.37 per share, mainly due to increased stock-based compensation and restructuring-related severance. Adjusted EBITDA turned positive to $4.3 million from $0.1 million, reflecting stronger underlying operations.
Anika is reshaping its cost structure after divesting Arthrosurface and Parcus Medical, focusing on OA Pain Management and Regenerative Solutions. It recorded about $1.6 million of severance and $3.3 million of stock-based expense tied to a CEO transition. Cash and equivalents were $41.0 million with no debt, after funding $8.7 million of share repurchases under a $40 million program.
Anika Therapeutics (ANIK) reported Q3 2025 results. Revenue was $27.8M with gross margin at 56%, producing a net loss of $2.3M and a loss from continuing operations of $3.2M. Adjusted EBITDA was $0.9M. For the nine months, revenue totaled $82.2M with gross margin at 54% and a net loss of $11.2M.
Channel mix shifted: OEM revenue declined 20% in Q3, driven by lower pricing from J&J MedTech, while Commercial Channel grew 22%. J&J MedTech represented 51% of Q3 revenue. Cash and cash equivalents were $58.0M, and no repurchases occurred in Q3 after completing the first $15.0M tranche of the $40.0M program by June 2025.
Strategically, Anika completed the sales of Arthrosurface and Parcus Medical and sharpened focus on OA Pain Management and Regenerative Solutions. J&J MedTech extended exclusive U.S. rights to market Monovisc through December 2031. For Hyalofast, the U.S. pivotal study did not meet co-primary endpoints, but the final PMA module was submitted on October 31, 2025, supported by improvements on key secondary endpoints.